Despite inducing potent and durable anti-tumor immunity, this approach has a limited function as monotherapy due to the lack of pre-existing T cell infiltration into the tumor microenvironment (TME), which leads to resistance to PD-1 blockade therapy2,3. The gene discussed is PDCD1; the disease is neoplasm.